Daniel Castellano
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
Papers in
-
- Renal cell carcinoma treatment 91
- Prostate Cancer Treatment and Research 74
- Oncology 163
- Cancer Immunotherapy and Biomarkers 71
- Co-authors
- Joaquim Bellmunt (53 shared papers)Elizabeth R. Plimack (20 shared papers)Ronald de Wit (35 shared papers)Thomas Powles (51 shared papers)Petros Grivas (24 shared papers)Ignacio Durán (52 shared papers)Peter H. O’Donnell (19 shared papers)Arjun Vasant Balar (21 shared papers)
- Journals
- Journal of Clinical Oncology (150 papers)Annals of Oncology (41 papers)European Journal of Cancer (16 papers)Cancer and Metastasis Reviews (11 papers)European Urology (9 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Daniel Castellano
355 papers receiving 9.9k citations
Daniel Castellano's Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 3.8k
- Pulmonary and Respiratory Medicine 3.5k
- Cancer Research 1.2k
- Surgery 3.0k
- Epidemiology 1.2k
Countries citing papers authored by Daniel Castellano
This map shows the geographic impact of Daniel Castellano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Castellano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Castellano more than expected).
Fields of papers citing papers by Daniel Castellano
This network shows the impact of papers produced by Daniel Castellano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Castellano. The network helps show where Daniel Castellano may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Castellano, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 375 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 959 |
| 2 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 709 |
| 3 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 457 |
| 4 | Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 386 |
| 5 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Hit paper breakdown → | 2020 | 355 |
| 6 | 2010 | 313 | |
| 7 | 2017 | 245 | |
| 8 | Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Hit paper breakdown → | 2020 | 204 |
| 9 | Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Hit paper breakdown → | 2021 | 188 |
| 10 | 2017 | 187 | |
| 11 | 2011 | 183 | |
| 12 | 2017 | 162 | |
| 13 | 1999 | 154 | |
| 14 | 2011 | 147 | |
| 15 | 2018 | 121 | |
| 16 | 2005 | 115 | |
| 17 | 2015 | 109 | |
| 18 | 2013 | 104 | |
| 19 | 2011 | 102 | |
| 20 | 2019 | 101 |
About Daniel Castellano
Daniel Castellano is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Molecular Biology, having authored 375 papers that have together received 10.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (112 papers), Renal cell carcinoma treatment (91 papers), Prostate Cancer Treatment and Research (74 papers), Cancer Immunotherapy and Biomarkers (71 papers), Cancer Genomics and Diagnostics (40 papers), Urinary and Genital Oncology Studies (40 papers), Neuroendocrine Tumor Research Advances (39 papers) and Radiopharmaceutical Chemistry and Applications (30 papers). The work is most often cited by research in Oncology (3.8k citations), Pulmonary and Respiratory Medicine (3.5k citations), Cancer Research (1.2k citations), Surgery (3.0k citations) and Epidemiology (1.2k citations). Daniel Castellano has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Joaquim Bellmunt, Elizabeth R. Plimack, Ronald de Wit, Thomas Powles, Petros Grivas, Ignacio Durán, Peter H. O’Donnell, Arjun Vasant Balar, Dean F. Bajorin and Jacqueline Vuky. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer and Metastasis Reviews and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.